ALNYAlnylam PharmaceuticalsHealth Care
$301.98EarningsJul 30, 2026
1D—1W—1M—3M—1Y—
Market cap$41.7BCompany infoRevenue$4.3B52-wk range$278 – $491IndustryBiotechnologyWebsitealnylam.comRelated
Yahoo
EDGAR
CNN
FinvizMarket Beat
Perform
n/a
1 Year
n/a1 Month
n/a1 Week
n/a1 Day
Rank Durability
Persist
n/a
1 Year
n/a6 Month
n/a3 Month
n/aTrend Hold
Business Beat
Profit
n/a
Composite
n/aRevenue
n/aMargin
n/aCash Flow
Money Flow
Pressure
n/a
60 Day
n/a30 Day
n/a5 Day
n/a2 Day
▼ −7.1% · 1YSPY
Weekly rank vs S&P 500 · 52wk
Not enough history to plot
ValuationHow the price is priced — vs cohort and vs its own past
MetricValueUnivSect5-yr range
P / E71.7×98
P / S9.7×108
9
30
P / FCF65.1×95
71
2202
EV / EBITDA65.2×31
72
327
P / E (fwd)40.3×——
ProfitabilityMargins and returns on capital
MetricValueUnivSect5-yr range
Gross margin80.9%9284
81%
87%
Operating margin17.5%5558
-109%
18%
Net margin13.5%6164
-129%
13%
ROE117.1%9899
-5781%
117%
ROIC30.4%9494
-107%
30%
Financial healthLeverage and liquidity
MetricValueUnivSect5-yr range
Debt / equity1.182817
0.5
75.7
Net debt / EBITDA-2.8×9294
Current ratio3.138475
Interest coverage2.7×2724
Per shareTTM, with year-over-year change
Revenue / share$31.01▲ +83%
EPS (diluted)$4.21▲ +301%
FCF / share$4.64▲ +951%
Est. EPS growth (fwd)+42%